December 2008

Splenic rupture, secondary to G-CSF use for chemotherapy induced neutropenia: a case report and review of literature.

Nehal Masood  
*Aga Khan University, nehal.masood@aku.edu*

Asim Jamal Shaikh  
*Aga Khan University*

Wasim Ahmed Memon  
*Aga Khan University*

Romana Idress  
*Aga Khan University*

Follow this and additional works at: https://ecommons.aku.edu/pakistan_fhs_mc_med_haematol_oncol

Part of the *Hematology Commons*, and the *Oncology Commons*

Recommended Citation

Masood, N., Shaikh, A., Memon, W., Idress, R. (2008). Splenic rupture, secondary to G-CSF use for chemotherapy induced neutropenia: a case report and review of literature. *Cases Journal, 1*(1), 418.

Available at: https://ecommons.aku.edu/pakistan_fhs_mc_med_haematol_oncol/5
Splenic rupture, secondary to G-CSF use for chemotherapy induced neutropenia: a case report and review of literature

Nehal Masood¹, Asim Jamal Shaikh*¹, Wasim Ahmed Memon² and Romana Idress³

Address: ¹Section of Oncology, Department of Medicine, the Aga Khan University Hospital, Karachi, Pakistan, ²Department of Radiology, the Aga Khan University Hospital, Karachi, Pakistan and ³Department of Pathology, the Aga Khan University Hospital, Karachi, Pakistan

Email: Nehal Masood - nehal.masood@aku.edu; Asim Jamal Shaikh* - asim.jshaikh@aku.edu; Wasim Ahmed Memon - wasim.memon@aku.edu; Romana Idress - romana.idrees@aku.edu

* Corresponding author

Abstract

Introduction: Chemotherapy Induced neutropenia is a frequent and serious complication of cytotoxic cancer treatment. Granulocyte colony stimulating factors (G-CSF) are frequently used to counter neutropenia, attempt rapid recovery of patients and allow for continuation of treatment without compromise on dose, especially in curative malignancies. Generally regarded as safe, G-CSF use has been very rarely reported to have resulted in serious side effects, such as, splenic rupture.

Case presentation: We are reporting a case of a twenty years old man, who was being treated for T cell acute lymphoblastic leukemia and received colony stimulating factors for treatment of severe neutropenia and suffered from splenic rupture, He was treated with splenectomy.

Conclusion: Although extremely rare, splenic rupture can be a serious and sometimes life threatening complication of high dose colony stimulating factors therapy.

Introduction

One of the most serious toxicity of chemotherapy is neutropenia, a complication that leads to infection, hospitalization, and even death. Dose reduction in subsequent cycles is also one of the compromise which has to be made in anticipation of troublesome neutropenia[1]. G-CSF therapy promote white blood cell (WBC) proliferation, maturation and functional capacity [2], they are widely used to treat myelosuppression caused by chemotherapy. By their effect of reducing the duration and severity of neutropenia, G-CSF use allows for continuation of cytotoxic chemotherapy, that is, in order to obtain superior long term results in various cancers[3]. The results of using G-CSF in primary prophylaxis for neutropenia are promising[4], however their effectiveness in treatment of established neutropenia remains controversial[5]. G-CSF use is the cornerstone of therapy, for hematopoietic stem cell mobilization for stem cell transplantation[3]. Therapy with G-CSF is generally regarded as safe, as side effects with doses as high as 600 $\mu$g/day, in healthy volunteers have been tolerated safely. Therapy induced high WBC counts tend to abate within 48 hours of withdrawal [6]. Side effects from long-term use as in patients with congenital neutropenia have also been regarded as generally safe with need of stopping therapy arising rarely if ever[7]. Myocardial infarction, stroke and splenic rupture are
some of the rare side effects of high dose G-CSF therapy. There are few reported cases of splenic rupture secondary to use of G-CSF so far, most of the reported patients were either healthy donors of stem cell transplant patients or patients undergoing peripheral blood stem cell mobilization for transplant (PBSCT) [2].

We here in report a case of a young patient suffering from T-cell lymphoblastic lymphoma, who received G-CSF as secondary prophylaxis and unfortunately suffered from splenic rupture.

**Case report**

A 20 years old gentleman was being treated for Acute T cell lymphoblastic lymphoma with hyper-CVAD regimen, the therapy consists of Cyclophosphamide, vincristine, doxorubicin and dexamethasone alternating with high dose methotrexate and cytarabine[8]. The patient suffered from severe neutropenia after the first cycle of therapy and required treatment with G-CSF prior to second, with the intention to obtain full benefit of chemotherapy and not compromising on dose. When followed in clinic he showed a low white cell count with an absolute neutrophil count (ANC) of 200 cells/microL on day 11 after cycle 2 despite being on G-CSF 300 μg/day for 9 days. He was advised to double the dose of G-CSF to 600 μg/day and instructed to return with a complete blood count in three days. About 10 days later he came to emergency room complaining of severe and sharp left upper quadrant pain radiating to shoulder. His white cell count was > 140 × 10^9/l. A CT scan was obtained in the emergency room (FIG 1) which showed splenomegaly with high density fluid noted around the spleen and pelvic region most likely representing hemoperitoneum. There was an irregularity noted posteriorly with in the spleen and the location of high density fluid raised the possibility of splenic rupture. Patient was initially treated with intravenous hydration and pain control, G-CSF was stopped. He under went successful splenectomy two days later, histopathology of which confirmed splenic rupture, splenic engorgement and evidence of extramedullary hemopoiesis (Fig 2). Patient’s counts returned to < 14 × 10^9/l, and he was discharged uneventfully. He is currently completing his treatment with remaining cycles of hyper-CVAD regimen.

**Discussion**

Treatment with G-CSF is commonly practiced in patients undergoing neutropenia secondary to chemotherapy for cancers. It is generally considered safe and effective, while many patients have derived benefits of therapy with G-CSF, developing less infection, less antibiotic use and shorter hospital stay, some suffer from minor self limited side effects as well [7]. Prophylactic G-CSF use is recommended when using a chemotherapy regimen associated with a risk of febrile neutropenia in > 20% patients, as is, its use in situations where dose-dense or dose-intense chemotherapy strategies have survival benefit [1]. Uninterrupted G-CSF therapy is recommended in patients undergoing treatment with hyper-CVAD until the white cell count has recovered to 3.0 × 10^9/L[8]. There have been case reports of splenic rupture in healthy donors of PBSCT patients or patients themselves undergoing mobilization. Two of such patients have reportedly died as a result while the rest were managed successfully with splenectomy [2,9]. Case reports appearing in literature following prophylactic G-CSF use are extremely rare[10].

To the best of our knowledge this is a rare case where G-CSF induced splenic rupture has been reported in patient suffering from acute lymphoblastic lymphoma. The patient presented with acute onset left sided pain without any history of trauma. He uninterruptedly took G-CSF for
About the authors
NM and AJS From the section of oncology, department of medicine: the Aga Khan University hospital, Karachi, Pakistan.

2. WAM from the department of radiology: the Aga Khan University hospital, Karachi, Pakistan.

3. RI from the department of pathology: the Aga Khan University hospital, Karachi, Pakistan.

References
1. Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J, Ellis M, et al.: EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. European journal of cancer 2006, 42(15):2433-53.

2. Nuamah NM, Goker H, Kilic YA, Dagmou H, Cakmak A: Spontaneous splenic rupture in a healthy allogeneic donor of peripheral-blood stem cell following the administration of granulocyte colony-stimulating factor (g-csf). A case report and review of the literature. Haematologica 2006, 91(5 Suppl):E208.

3. Lienne-Huyghe P, Kuhnowski F, Coiteux V, Bauters F, Morschhauser F: [Indications of G-CSF administration in hematologic disorders]. Bulletin du cancer 93(5):453-62.

4. Kuderer NM, Dale DC, Crawford J, Lyman GH: Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 25(21):3158-67.

5. Berghmans T, Paesmans M, Lafitte J, Marschall E: The incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoid malignancies: a prospective study. Support Care Cancer 2002, 10(3):181-8.

6. Borleffs JC, Bosschaert M, Vreken F, Schneider MM, van Strijp J, Small MK, et al.: Effect of escalating doses of recombinant human granulocyte colony-stimulating factor (filgrastim) on circulating neutrophils in healthy subjects. Clinical therapeutics 1998, 20(4):722-36.

7. Freedman MH: Safety of long-term administration of granulocyte colony-stimulating factor for severe chronic neutropenia. Current opinion in hematology 1997, 4(3):217-24.

8. Kantarjian HM, O'Brien S, Smith TL, Cortes J, Giles FJ, Beran M, et al.: Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000, 18(3):547-61.

9. O'Malley DP, Whalen M, Banks PM: Spontaneous splenic rupture with fatal outcome following G-CSF administration for myelodysplastic syndrome. American journal of hematology 2003, 73(4):294-5.

10. Watring NJ, Wagner TW, Stark J: Spontaneous splenic rupture secondary to pegfilgrastim to prevent neutropenia in a patient with non-small-cell lung carcinoma. The American journal of emergency medicine 2007, 25(2):247-8.

11. Stroncek D, Shawker T, Follmann D, Leitman SF: G-CSF-induced spleen size changes in peripheral blood progenitor cell donors. Transfusion 2003, 43(5):609-13.